
‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia
Bristol Myers Squibb’s schizophrenia drug Cobenfy failed to significantly ease symptom severity when used alongside atypical antipsychotics in patients with schizophrenia, according to a topline readout from the Phase III ARISE trial on Tuesday. Analysts …